2016 American Transplant Congress
Utilization of HCV-Positive Donors' Kidneys: Potential Benefits in the Era of Direct Acting Antiviral (DAA) Therapy.
Organ shortage and expanding kidney waiting list fostered utilization of HCV positive donors' organs (HCVD+). HCVD+ kidneys have slightly worse long term outcomes compared with…2016 American Transplant Congress
Utilization and Discard of HCV+ Donor Livers in the Advent of Direct-Acting Antiviral Therapy.
While 45% of liver candidates are hepatitis C (HCV)-antibody positive (+) and might benefit from a HCV+ donor liver, only a small proportion receive one.…2016 American Transplant Congress
Direct-Acting Antivirals for Hepatitis C Treatment in Kidney Transplant Recipients.
University of Minnesota, Minneapolis.
Background: Hepatitis C infection is associated with worse clinical outcomes in kidney transplant recipients. Direct-acting antivirals (DAAs) have been effectively used in liver transplant patients…2016 American Transplant Congress
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.
Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…2015 American Transplant Congress
Outcomes of Hepatitis C Virus (HCV) Treatment Following Liver Transplantation in the Era of Direct-Acting Antiviral Medications
BACKGROUND: The treatment of HCV is one of the most rapidly changing areas of medical practice. These agents have been shown to be safe and…2015 American Transplant Congress
High Tolerability With Sofosbuvir-Based Direct-Acting Antiviral Therapy in Liver Transplant Recipients With Recurrent Hepatitis C
Background: Reports on efficacy, safety, and tolerability of sofobuvir-based antiviral regimens in liver transplant recipients with recurrent hepatitis C are limited. Methods: We performed a…2015 American Transplant Congress
Long-Term Outcome of Liver Transplant Recipients (OLT) With Hepatitis C Recurrence (HCVR) Who Achieved Postoperative Sustained Virologic Response (SVR) After Combination Antiviral Therapy (Rx) With and Without the Use of Telaprevir (TVR): A Single Center Experience
Liver Institute, Methodist Dallas Medical Center, Dallas, TX.
Aim: Liver allografts of viremic OLT have a higher risk of failure. Timely intervention is necessary. However, long-term outcome reports, especially using newer agents, is…2015 American Transplant Congress
Sofosbuvir-Based Therapy for Hepatitis C Recurrence Post Liver Transplantation
Introduction:Sofosbuvir is approved to treat HCV infection in all genotypes with sustained virological response 12 weeks after completion of therapy (SVR12)rates of up to 100%.…2015 American Transplant Congress
Screening Recipients of Increased Risk Donor Organs: A Multicenter Study
Purpose: Policy mandates post-transplant (tx) evaluation of recipients of increased risk donor organs (ROIRDO). PHS guidelines recommend that screening include HIV & hepatitis C virus…2015 American Transplant Congress
End of Treatment Liver Biopsy With Sofosbuvir: Histologic Changes Suggestive of Hepatitis C Activity in Liver Transplant Recipients With Achieved SVR
Background: Interferon (IFN) free HCV regimens are associated with better tolerability and efficacy. The majority of studies report biochemical and virological response; however limited information…
American Transplant Congress abstracts